Drug Profile
Seribantumab - Elevation Oncology
Alternative Names: MM-121; SAR-256212Latest Information Update: 12 Apr 2024
Price :
$50
*
At a glance
- Originator Merrimack Pharmaceuticals
- Developer Elevation Oncology; Merrimack Pharmaceuticals; Sanofi
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Solid tumours
Highest Development Phases
- Suspended Solid tumours
- Discontinued Gynaecological cancer; HER2 negative breast cancer; Non-small cell lung cancer; Ovarian cancer
Most Recent Events
- 11 Apr 2024 Interim pharmacodynamics data from a preclinical studies in HER2 expressing cancer released by Elevation Oncology
- 14 Apr 2023 Safety and efficacy data from a phase II CRESTONE trial in Solid tumours presented at the 114th Annual Meeting of the American Association for Cancer Research (AACR-2023)
- 06 Jan 2023 Seribantumab - Elevation Oncology is available for licensing as of 06 Jan 2023. https://elevationoncology.com/our-focus-step-4/# 9378199